

Product datasheet for RC203786L3V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

OLFM2 (NM_058164) Human Tagged ORF Clone Lentiviral Particle

Product data:

Product Type: Lentiviral Particles

Product Name: OLFM2 (NM_058164) Human Tagged ORF Clone Lentiviral Particle

Symbol: OLFM2

Synonyms: NOE2; NOELIN2; NOELIN2_V1; OlfC

Mammalian Cell

Selection:

Puromycin

Vector: pLenti-C-Myc-DDK-P2A-Puro (PS100092)

Tag:Myc-DDKACCN:NM_058164

ORF Size: 1362 bp

ORF Nucleotide

The ORF insert of this clone is exactly the same as(RC203786).

OTI Disclaimer:

Sequence:

The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing

variants is recommended prior to use. More info

OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression

varies depending on the nature of the gene.

RefSeq: <u>NM 058164.1</u>

 RefSeq Size:
 1899 bp

 RefSeq ORF:
 1365 bp

 Locus ID:
 93145

 UniProt ID:
 095897

 Cytogenetics:
 19p13.2

Domains: OLF

Protein Families: Druggable Genome, Secreted Protein





ORIGENE

MW: 51.4 kDa

Gene Summary:

Involved in transforming growth factor beta (TGF-beta)-induced smooth muscle differentiation. TGF-beta induces expression and translocation of OLFM2 to the nucleus where it binds to SRF, causing its dissociation from the transcriptional repressor HEY2/HERP1 and facilitating binding of SRF to target genes (PubMed:25298399). Plays a role in AMPAR complex organization (By similarity). Is a regulator of vascular smooth-muscle cell (SMC) phenotypic switching, that acts by promoting RUNX2 and inhibiting MYOCD binding to SRF. SMC phenotypic switching is the process through which vascular SMCs undergo transition between a quiescent contractile phenotype and a proliferative synthetic phenotype in response to pathological stimuli. SMC phenotypic plasticity is essential for vascular development and remodeling (By similarity).[UniProtKB/Swiss-Prot Function]